SCHEMBL262885

SCHEMBL262885

COc1cc(Cl)cc(-c2ccc(NC(=O)c3conc3C)nc2N)c1Cl

nearest known ligand 0.79

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 13/20 0.79
SCN9A Q15858 4/20 0.59
SCN2A Q99250 3/20 0.59
SCN3A Q9NY46 3/20 0.59
SCN5A Q14524 3/20 0.59
NPC1 O15118 2/20 0.46
MAPT P10636 1/20 0.46
SCN1A P35498 2/20 0.44
KCNH2 Q12809 1/20 0.40
FGFR3 P22607 2/20 0.40
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
F10 P00742 2/20 0.38
PDE10A Q9Y233 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263548 0.88 SCN10A (1.00) SCN10ASCN9ASCN2ASCN3ASCN5A
SCHEMBL2413029 0.85 SCN10A (0.80) SCN10ASCN9ASCN2ASCN3ASCN5A
SCHEMBL14237458 0.85 SCN10A (0.81) SCN10ASCN9ASCN2ASCN3ASCN5A
SCHEMBL263242 0.84 SCN10A (0.55) SCN10ASCN9ASCN2ASCN3ASCN5A
SCHEMBL14237554 0.83 SCN10A (0.80) SCN10ASCN9ASCN2ASCN3ASCN5A
SCHEMBL14237329 0.83 SCN10A (0.76) SCN10ASCN9ASCN2ASCN3ASCN5A
SCHEMBL14237596 0.82 SCN10A (0.65) SCN10ASCN9ASCN2ASCN3ASCN5A
SCHEMBL263118 0.82 SCN10A (1.00) SCN10ASCN9ASCN2ASCN3ASCN5A
SCHEMBL14237710 0.82 SCN10A (0.83) SCN10ASCN9ASCN2ASCN3ASCN5A
SCHEMBL14237294 0.81 SCN10A (0.69) SCN10ASCN9ASCN2ASCN3ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP claimed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US claimed
JP-4657384-B2 2011-03-23 JP claimed
JP-2010526050-A 2010-07-29 JP claimed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP claimed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US claimed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO claimed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 SCN10A 358/4885SCN9A 491/4885SCN2A 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.